Article

Medicare to Pay Bonuses for E-prescribing-August 2008

Author(s):

Medicare will pay bonuses to providers who use e-prescribing, a move expected to reduce medication errors and save millions in costs due to adverse drug events.

Medicare is taking new steps to speed the adoption of electronic prescribing (e-prescribing) by offering bonuses to those who use the technology. The Department of Health and Human Services (HHS) says e-prescribing would eliminate thousands of medication errors every year.

Physicians who prescribe electronically for Part D patients will receive a 2% incentive payment in 2009 and 2010; a 1% incentive payment in 2011 and 2012; and a 0.5% incentive payment in 2013. After 5 years, bonuses for e-prescribing will be phased out.

Starting in 2012, those still using paper-only Rxs will receive a reduction in payment; however, some may be exempted from the payment reduction if it is determined that compliance with the new program would result in significant hardship, (eg, a doctor who practices in a rural area with insufficient Internet access).

HHS reports that Medicare will save up to $156 million over the 5 years of the program in avoided adverse drug events. It has been estimated that Medicare beneficiaries experience as many as 530,000 adverse drug events every year, contributed to, in part, by negative interactions with other drugs or a prescriber’s lack of information about the patient’s medication history.

The National Community Pharmacists Association (NCPA) reports that >90% of the nation’s pharmacies are certified to receive prescriptions electronically. Pharmacy leaders note that e-prescribing not only improves the accuracy of prescriptions but gives pharmacists more time for counseling patients by reducing time spent in verifying paper prescriptions.

“Electronic prescribing is an important part of community pharmacy’s overall effort to enhance quality, minimize medication errors, and improve patient outcomes,” noted Bruce Roberts, RPh, NCPA executive vice president and chief executive officer.

The National Alliance of State Pharmacy Associations is gathering information about pharmacists’ e-prescribing experiences; they can be reported at

.

www.pqc.net/eprescribe/disclaimer.htm

Related Videos
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Christopher Bunick, MD, PhD: Facts About Systemic Therapies’ Safety, Mechanism of Action
Carla Nester, MD | Credit: HCPLive
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
© 2024 MJH Life Sciences

All rights reserved.